IMDNA provides scientific, technical, and non-regulatory support for analytical verification and validation of qPCR, RT-qPCR, multiplex nucleic-acid assays, ELISA, multiplex bead-based immunoassays, flow cytometry, cell-based assays, and other laboratory methods within IMDNA's technical expertise. Support can include study design, draft protocols, QC and reference materials, precision studies, agreement/bias studies, linearity and range, detection capability, analytical specificity, interference and matrix-effect studies, robustness assessment, technical data review, troubleshooting, optimization, documentation, and implementation support.
Analytical verification and validation should answer a defined scientific question: does the method perform as expected for its intended use, sample type, instrument, workflow, and laboratory environment? The study design should therefore be matched to the method rather than applying the same performance package to every assay. IMDNA can help laboratories build that evidence while the laboratory retains responsibility for determining applicable requirements, approving protocols and acceptance criteria, conducting required studies, and authorizing the method for use.
For applicable U.S. nonwaived clinical testing, 42 CFR §493.1253 distinguishes verification of manufacturer-established performance specifications for unmodified FDA-cleared or approved systems from establishment of performance specifications for modified, laboratory-developed, or other applicable methods. CLSI guidance likewise separates verification of existing claims from broader studies used to establish analytical performance.
Define whether the assay is unmodified, modified, laboratory-developed, transferred, multiplexed, quantitative, qualitative, or used on a new platform.
Clarify analyte, specimen, matrix, concentration range, qualitative or quantitative output, instrument, and intended application.
Select studies that answer the scientifically relevant questions for the method instead of using a universal checklist without justification.
Define measurable criteria before study execution using applicable claims, prior data, literature, reference materials, or scientifically justified laboratory expectations.
Use the generated data to support laboratory decisions about method capability, limitations, transfer, optimization, and implementation.
Support can range from one defined analytical study to a coordinated verification or validation package.
Define study objectives, performance characteristics, concentration levels, replicates, runs, operators, instruments, materials, comparators, and technical endpoints.
Prepare draft analytical protocols, sample maps, run sheets, data worksheets, deviation forms, and report templates for laboratory review.
Help organize proposed technical criteria based on manufacturer claims, intended use, laboratory requirements, recognized guidance, prior assay data, or scientific justification.
Where appropriate and available, help identify or provide controls, standards, calibrators, reference materials, contrived materials, synthetic targets, or other study-support materials.
Support within-run, between-run, day-to-day, operator, instrument, lot, or site variability studies appropriate to the assay.
Support comparison with assigned values, reference materials, comparator methods, consensus results, or other scientifically justified benchmarks.
Plan concentration-series studies to evaluate response across the expected analytical or reportable interval.
Support evaluation of limit of blank, limit of detection, limit of quantitation, or qualitative low-level detection where relevant.
Evaluate intended target discrimination, cross-reactivity, inclusivity/exclusivity, homologous sequences, related analytes, nonspecific amplification, or nonspecific binding.
Support studies involving endogenous/exogenous interferents, inhibitors, matrix effects, extraction effects, sample conditions, or competing analytes.
Evaluate the impact of realistic changes in timing, temperature, reagent concentration, operator technique, lot, instrument, workflow, or sample processing.
Assist with evaluation of study outputs, outliers, discordance, performance trends, deviations, limitations, troubleshooting, and technical conclusions.
IMDNA's support framework moves from defining the assay and intended performance through evidence generation, technical review, corrective work, and documented implementation.
Not every performance characteristic applies in the same way to every assay. The appropriate analytical package depends on whether the output is quantitative or qualitative, the nature of the analyte, sample matrix, measurement technology, concentration range, and intended use.
How reproducible is the method across replicates, runs, days, operators, lots, instruments, or sites?
How closely do results agree with assigned values, comparator methods, reference materials, or expected classifications?
Across what concentration interval does the measurement response remain technically appropriate?
At what low analyte levels can blank, detection, or quantification performance be meaningfully characterized?
Can the assay distinguish the intended target from related sequences, organisms, analytes, or nonspecific signal?
Do sample components, inhibitors, competing molecules, sample-processing conditions, or matrix differences change results?
Does the assay remain stable under small, realistic variations in operating conditions?
Where relevant, are reference values, cutoffs, or interpretive ranges appropriate for the intended laboratory population or study design?
For qPCR and RT-qPCR, analytical validation must address the molecular behavior of the assay itself. MIQE 2.0 emphasizes assay specificity, amplification efficiency, linearity, dynamic range, controls, detection/quantification limits, sample handling, normalization, and transparent data analysis.
Review primer/probe specificity, target homology, sequence variants, pseudogenes, related organisms, transcript variants, nonspecific amplification, and potential cross-reactivity.
Evaluate dilution-series performance and determine whether assay kinetics remain consistent across the intended working range.
Assess quantitative response or qualitative detection consistency across defined target concentrations.
Use replicate testing at low analyte levels and an appropriate statistical or empirical framework for the intended assay.
Evaluate sample-matrix effects, extraction carryover, endogenous inhibitors, dilution response, and internal-control behavior.
Assess whether upstream extraction, lysis, purification, storage, or sample preparation materially changes target recovery or reproducibility.
Compare singleplex/lower-plex and final multiplex configurations to identify competition, channel effects, target-abundance imbalance, or sensitivity loss.
Support positive, negative, process, extraction, internal amplification, endogenous, exogenous, or no-RT controls depending on the workflow.
Support bridging studies after changes in master mix, primer/probe lot, extraction chemistry, instrument, software, or other critical components.
Analytical study design should reflect the molecular configuration that will actually be used.
The strongest study asks explicit questions rather than collecting data without a predefined objective.
CLSI MM17 specifically addresses the added analytical complexity of multiplex nucleic-acid assays, including specimen and reagent considerations, reference/QC materials, data analysis, verification/validation, and multiplex-specific performance. A multiplex assay should therefore be evaluated as an integrated analytical system rather than assuming that singleplex performance automatically transfers to the multiplex configuration.
Evaluate whether highly abundant targets reduce amplification or detection of lower-abundance targets in the same reaction.
Compare relevant target performance before and after multiplex integration, especially near the low end of the analytical range.
Review fluorophore compatibility, spectral separation, optical calibration, baseline behavior, and analysis settings.
For infectious or sequence-variable targets, evaluate relevant target diversity and closely related non-target sequences or organisms.
Confirm that internal or process controls monitor the reaction without consuming excessive reaction resources or masking weak targets.
Evaluate low-level detection in the final multiplex context rather than assuming the LOD observed in isolated singleplex assays.
The technical scope depends on what is already known about the method and what has changed.
| Method Situation | General Analytical Question | IMDNA Support May Include |
|---|---|---|
| Unmodified FDA-cleared / approved nonwaived method | Can the laboratory reproduce applicable manufacturer-established performance specifications in its own environment? | Verification protocol support, precision, comparison/accuracy, reportable-range studies, reference-range support, QC materials, data review. |
| Modified method | Has the modification changed any analytical performance characteristic relevant to the intended use? | Change-impact review, precision, range, sensitivity, specificity, interference, comparator studies, controls, optimization. |
| Laboratory-developed method | What performance characteristics must be established to demonstrate analytical suitability for the intended laboratory use? | Validation-plan support, reference materials, precision, agreement, detection capability, specificity, interference, robustness, data review. |
| Transferred method | Does the receiving laboratory reproduce acceptable performance after transfer? | Gap assessment, cross-validation/bridging, comparison studies, shared materials, transfer documentation, troubleshooting. |
| New multiplex configuration | Does combining targets materially alter sensitivity, specificity, precision, channel separation, or controls? | Multiplex equivalence, competition studies, channel review, panel-specific LOD, specificity/inclusivity/exclusivity, optimization. |
CLSI Evaluation Protocols provide distinct frameworks for different analytical questions. EP15 focuses on user verification of precision claims and estimation of bias; EP09 addresses measurement-procedure comparison and bias using patient samples; EP17 addresses LoB, LoD, and LoQ; other EP documents address linearity, interference, qualitative performance, reference intervals, and related questions.
For previously established quantitative methods, support verification of precision claims and bias estimation using a structured short-duration study.
Support patient-sample or representative-sample comparison using appropriate regression/agreement methods rather than relying on correlation alone.
Support LoB, LoD, and LoQ studies where applicable, including low-level replicate design and appropriate interpretation.
Support verification or establishment of the relationship between expected concentration and observed response across the measuring interval.
Evaluate whether defined endogenous or exogenous interferents materially change the reported result.
Support categorical performance evaluation using positive/negative agreement, cutoff behavior, low-level samples, discordance review, and appropriate qualitative statistics.
Calibration curve, precision, bias/agreement, analytical sensitivity, dilution linearity, spike recovery, parallelism, specificity, interference, matrix effects, reader performance, and robustness.
Analyte-specific precision, common dilution effects, calibration range, cross-talk, matrix effects, interference, bead/reagent stability, and analyte-specific recovery.
Instrument QC, precision, reproducibility, antibody/reagent lots, sample stability, compensation/unmixing, gating consistency, rare-event behavior, and analytical comparability.
Cell-state consistency, response window, precision, plate effects, passage effects, controls, treatment response, biological variability, robustness, and repeatability.
Recovery, reproducibility, inhibition, yield, purity, matrix dependence, carryover, lot effects, and compatibility with downstream measurement.
Before/after comparison, bridging, precision checks, analytical-range review, controls, software settings, and method-transfer support.
A strong analytical study does not hide unexpected findings. Outliers, failed criteria, discordant samples, control shifts, and matrix-dependent behavior may reveal important limitations or opportunities for method improvement.
Determine whether study controls behaved as expected and whether any control issue limits interpretation of the run or study.
Evaluate technical, sample, instrument, operator, lot, or biological explanations rather than removing data without documented justification.
Review sample identity, comparator limitations, target abundance, matrix effects, analytical specificity, reagent lots, and analysis settings.
Determine whether the appropriate response is optimization, additional data, method limitation, redesign, or a revised scientifically justified study.
Document protocol deviations, technical impact, repeat work, corrective action, and how the deviation affects the final conclusion.
After a technical change, repeat the affected performance study to confirm that improvement is reproducible and does not create new limitations.
IMDNA provides general scientific, technical, analytical-verification, analytical-validation, assay-development, QC/reference-material, troubleshooting, optimization, documentation, and non-regulatory implementation support based on the needs of each laboratory organization. Support may include assistance with study planning, draft protocols, acceptance-criteria organization, precision, agreement/bias, linearity, measuring range, detection capability, analytical specificity, interference, matrix effects, robustness, multiplex equivalence, reference materials, data review, troubleshooting, technical reports, and implementation support.
Where appropriate, IMDNA may provide scientific guidance, analytical study templates, reference or QC materials, sequence-based assay review, comparison-study support, technical data review, troubleshooting plans, and documentation through its scientific, technical, and laboratory-experienced team.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, governmental, or inspecting authority. IMDNA does not independently certify that a method is clinically valid, approve a laboratory's final acceptance criteria, authorize patient testing, or guarantee that an analytical study will satisfy every applicable requirement.
Each laboratory is responsible for determining which analytical verification or validation requirements apply to its own method and intended use; approving protocols and acceptance criteria; conducting and documenting required studies; interpreting final results; approving the method; and determining whether additional verification, validation, requalification, manufacturer service, accreditation review, or regulatory action is required.
Any analytical protocol, study design, technical recommendation, data review, template, or report provided by IMDNA is intended to support the laboratory's own scientific and technical work and should not be interpreted as regulatory approval, accreditation, certification, legal determination, reimbursement determination, or guarantee of regulatory acceptance.
References to governmental, regulatory, scientific, standards-development, manufacturer, or professional organizations are provided for general informational purposes only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA or its services.
The following official and consensus-standard resources support the general concepts of analytical verification, validation, precision, comparison, detection capability, multiplex molecular performance, qPCR quality, and analytical lifecycle management. They are provided for independent scientific reference and do not imply endorsement of IMDNA.
Tell IMDNA about your assay technology, target or analyte, sample type, instrument, comparator, controls, expected analytical range, current performance, method status, available reference materials, and validation objectives. Our scientific and technical team can help organize a verification or validation plan covering molecular specificity, precision, comparison, linearity, detection capability, matrix/interference studies, multiplex behavior, troubleshooting, technical reporting, and implementation support.